Sermorelin dosage: what to expect from your first prescription

You already know that growth hormone output drops roughly 14-15% per decade after your mid-20s. You feel it not as a single obvious failure but as a slow accumulation of small losses — recovery takes a day longer, body composition shifts despite consistent training, sleep feels lighter. Sermorelin is a growth hormone-releasing hormone (GHRH) analogue that prompts your pituitary gland to release more of your own growth hormone. It does not introduce synthetic growth hormone into your body. That distinction matters for both safety and physiology, and it shapes how the dosing protocol works.

What sermorelin actually does before we talk numbers

Sermorelin is a 29-amino-acid peptide that mirrors the first 29 amino acids of endogenous GHRH. When it binds to GHRH receptors on somatotroph cells in your anterior pituitary, those cells release growth hormone in a pulse. Your body's natural feedback loop — primarily through somatostatin — remains intact. This means you still have a physiological brake. Compare that to exogenous recombinant human growth hormone (rhGH), which bypasses the pituitary entirely and suppresses your natural axis over time. With sermorelin, your hypothalamic-pituitary axis keeps doing its job; you are just giving it a stronger signal.

The clinical evidence base is modest in scale but consistent in direction. Khorram et al. (1997, PMID 9141536) conducted one of the more rigorous early trials, a double-blind placebo-controlled study in older adults using nightly sermorelin injections. They documented significant increases in IGF-1, improved sleep quality (specifically slow-wave sleep depth), and changes in body composition. The trial was small — 89 subjects — and the participants were elderly, not 44-year-old men who train regularly. That context matters when you apply the findings to yourself. Walker (2006, PMC2699646) later reviewed the broader evidence for GHRH analogues and noted that the pulsatile, feedback-regulated mechanism makes these peptides a pharmacologically cleaner approach than direct GH replacement, particularly for long-term use. Again, much of the underlying data comes from older or clinically deficient populations. Extrapolating to a healthy, active adult requires intellectual honesty.

Typical starting doses and how they are determined

Compounded sermorelin is dispensed as a lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water and inject subcutaneously — typically into abdominal fat — using an insulin syringe. The dose is measured in micrograms (mcg), not milligrams. That is not a trivial distinction; concentration errors are one of the most common mistakes new users make, so confirm your reconstitution math with your prescribing provider before your first injection.

The most commonly prescribed starting range in clinical practice is 200-300 mcg per night, injected at bedtime. Nighttime dosing is deliberate. Growth hormone is naturally secreted in pulses during slow-wave sleep. Administering sermorelin 30-60 minutes before sleep aligns the drug's peak action with the window when your pituitary is already most responsive. Some protocols use twice-daily dosing — morning on an empty stomach and again at night — particularly when the clinical goal includes body composition change rather than sleep quality alone. Your prescriber will tailor this based on your intake data, symptom profile, and baseline IGF-1 levels if labs are available.

• Starting dose: typically 200-300 mcg subcutaneously at bedtime
• Titration: many providers adjust upward to 300-500 mcg after 4-8 weeks based on symptom response and IGF-1 trend
• Twice-daily protocols: 100-200 mcg in the morning (fasted) plus 200-300 mcg at night — used selectively
• Cycle structure: commonly prescribed as 5 days on, 2 days off, or continuous — protocols vary by provider and goal
• Injection site: subcutaneous, rotating abdominal or thigh sites to avoid lipodystrophy

One practical note: food significantly blunts the GH pulse. Elevated blood glucose and free fatty acids both stimulate somatostatin release, which suppresses the pituitary response to GHRH. If you are dosing at night, a two-hour fast before injection is a standard recommendation. If you eat a large dinner late, your dose is working against your own physiology.

What to expect in the first 90 days

The timeline for sermorelin is slower than most people expect. This is not a drug that produces noticeable effects in week one. The mechanism requires building up pulsatile GH output over time and allowing downstream effects — primarily mediated through IGF-1 produced in the liver — to accumulate.

• Weeks 1-3: improved sleep depth is often the earliest reported effect — some users notice this within the first week, others do not notice it at all
• Weeks 4-8: energy and recovery may start to shift; this is subjective and highly individual
• Months 2-3: IGF-1 levels typically begin rising measurably; body composition changes (modest reduction in fat mass, modest increase in lean mass) become detectable with accurate measurement methods
• Month 3+: the most reliable objective marker is a follow-up IGF-1 lab draw; a response that keeps IGF-1 in the upper-normal physiological range for your age is the target — not supraphysiologic elevation

Side effects at therapeutic doses are generally mild. The most commonly reported are injection-site redness or itching (usually transient), temporary water retention during the first few weeks as IGF-1 rises, and occasional flushing shortly after injection. Joint discomfort and peripheral edema are more associated with supraphysiologic dosing or exogenous GH and are less typical at standard sermorelin doses. If you develop persistent edema, carpal tunnel symptoms, or feel your resting heart rate or blood pressure trending upward, those are signals to contact your provider and reassess dose.

Monitoring: the number that tells you if it is working

Sermorelin's effect cannot be reliably tracked by how you feel alone. IGF-1 is the primary biomarker. It is a stable proxy for integrated GH output — unlike GH itself, which is pulsatile and highly variable if you measured it directly. A baseline IGF-1 before starting, then a follow-up at 8-12 weeks, gives your provider objective data to determine whether the current dose is producing a meaningful response or needs adjustment.

The target is not the highest IGF-1 you can produce. Reference ranges are age-adjusted, and the goal is to restore your level to the upper-normal range for a healthy adult your age — roughly 150-250 ng/mL for most men in their 40s, though lab-specific ranges vary. Driving IGF-1 above physiologic norms introduces risks, including theoretically increased mitogenic signaling, that are not justified by the evidence for a healthy, functional adult. Your provider should be having this conversation with you explicitly.

One more thing worth saying plainly: the evidence base for sermorelin in healthy, active middle-aged men specifically is thin. Most trials involved elderly or growth-hormone-deficient subjects. What we know about mechanism is solid; what we know about long-term outcomes in your demographic is largely extrapolated. That is not a reason to avoid it if your clinical picture supports it — but it is a reason to work with a provider who monitors you rather than one who simply ships you a vial.